Lux Biosciences, Inc.

LX214

LX214 is a proprietary formulation of Lux Biosciences’ next generation calcineurin inhibitor that has been developed for topical ophthalmic use in collaboration with the University of Missouri at Kansas City. Unlike other topical dry eye products and product candidates with similar mechanism of action, LX214 is a crystal clear, aqueous formulation. In addition to the unique features of the formulation, LX214 contains high concentration of LX211/ISA247 and, based on preliminary testing, appears to be non-irritating. The next generation calcineurin inhibitor LX211/ISA247 is licensed to Lux Biosciences for ophthalmic use by Isotechnika, Inc.

LX214 is currently in late preclinical development. IND submission and the first human studies are targeted for mid-2008. The product will initially be developed for mild to moderate Dry Eye Syndrome (DES).